TP53 and B-cell chronic lymphocytic leukemia: More importantly, around 2.5–4.5% of patients requiring front-line therapy harbor TP53 gene mutations without del17p [6, 8–10], supporting the notion that in CLL mutational analysis of TP53 gene is complementary to the standard assessment of del17p by fluorescent in situ hybridization (FISH).